CN101854937A - 新的stat3途径抑制剂和癌症干细胞抑制剂 - Google Patents
新的stat3途径抑制剂和癌症干细胞抑制剂 Download PDFInfo
- Publication number
- CN101854937A CN101854937A CN200880115247A CN200880115247A CN101854937A CN 101854937 A CN101854937 A CN 101854937A CN 200880115247 A CN200880115247 A CN 200880115247A CN 200880115247 A CN200880115247 A CN 200880115247A CN 101854937 A CN101854937 A CN 101854937A
- Authority
- CN
- China
- Prior art keywords
- substituted
- aryl
- alkyl
- heterocycle
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
化合物编号 | Stat3-Luc测定中的IC50 |
401 | ~0.25μM |
416 | ~0.75μM |
化合物编号 | Stat3-Luc测定中的IC50 |
418 | ~0.75μM |
402 | ~0.75μM |
412 | ~0.75μM |
410 | ~1μM |
409 | ~2μM |
408 | ~2μM |
301 | ~2μM |
407 | ~5μM |
抑制%化合物 1×MTT IC50 3×MTT IC50 |
418 39 63420 47 63302 6 25106 26 51202 50 46402 29 57301 20 26406 16 34103 98 26304 25 55 |
IC50(μM)化合物 NSP SP |
420 0.51 0.59401 0.33 0.34418 0.33 0.34402 0.38 0.4302 1.29 2.06106 2 4.44 |
IC50(μM)化合物 CD44低 CD44高 |
202 2.25 2.4304 2.49 2.41302 3.68 0.68 |
Claims (50)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97114407P | 2007-09-10 | 2007-09-10 | |
US60/971,144 | 2007-09-10 | ||
US1337207P | 2007-12-13 | 2007-12-13 | |
US61/013,372 | 2007-12-13 | ||
PCT/US2008/075848 WO2009036059A2 (en) | 2007-09-10 | 2008-09-10 | Novel stat3 pathway inhibitors and cancer stem cell inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310052882.1A Division CN103288787B (zh) | 2007-09-10 | 2008-09-10 | 新的stat3 途径抑制剂和癌症干细胞抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101854937A true CN101854937A (zh) | 2010-10-06 |
CN101854937B CN101854937B (zh) | 2013-03-27 |
Family
ID=40452461
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880115249.XA Active CN101854802B (zh) | 2007-09-10 | 2008-09-10 | 用于癌症治疗的组合物和方法 |
CN201310052882.1A Active CN103288787B (zh) | 2007-09-10 | 2008-09-10 | 新的stat3 途径抑制剂和癌症干细胞抑制剂 |
CN201610134121.4A Active CN105963289B (zh) | 2007-09-10 | 2008-09-10 | 一类stat3通路抑制剂和癌干细胞通路抑制剂 |
CN201410583457.XA Active CN104586832B (zh) | 2007-09-10 | 2008-09-10 | 用于癌症治疗的组合物和方法 |
CN2008801152470A Active CN101854937B (zh) | 2007-09-10 | 2008-09-10 | 新的stat3途径抑制剂和癌症干细胞抑制剂 |
CN200880115250.2A Active CN101854930B (zh) | 2007-09-10 | 2008-09-10 | 一类新的stat3通路抑制剂和癌干细胞通路抑制剂 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880115249.XA Active CN101854802B (zh) | 2007-09-10 | 2008-09-10 | 用于癌症治疗的组合物和方法 |
CN201310052882.1A Active CN103288787B (zh) | 2007-09-10 | 2008-09-10 | 新的stat3 途径抑制剂和癌症干细胞抑制剂 |
CN201610134121.4A Active CN105963289B (zh) | 2007-09-10 | 2008-09-10 | 一类stat3通路抑制剂和癌干细胞通路抑制剂 |
CN201410583457.XA Active CN104586832B (zh) | 2007-09-10 | 2008-09-10 | 用于癌症治疗的组合物和方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880115250.2A Active CN101854930B (zh) | 2007-09-10 | 2008-09-10 | 一类新的stat3通路抑制剂和癌干细胞通路抑制剂 |
Country Status (15)
Country | Link |
---|---|
US (12) | US9745278B2 (zh) |
EP (6) | EP2200431B1 (zh) |
JP (16) | JP5688840B2 (zh) |
CN (6) | CN101854802B (zh) |
CA (4) | CA2736532C (zh) |
CY (3) | CY1117604T1 (zh) |
DK (4) | DK3050566T3 (zh) |
ES (3) | ES2583010T3 (zh) |
HK (3) | HK1148943A1 (zh) |
HR (3) | HRP20160430T1 (zh) |
HU (3) | HUE027657T2 (zh) |
PL (4) | PL2194987T3 (zh) |
PT (2) | PT2194987T (zh) |
SI (3) | SI2190429T1 (zh) |
WO (3) | WO2009036099A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012119265A1 (en) * | 2011-03-04 | 2012-09-13 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES |
WO2013120229A1 (en) * | 2012-02-17 | 2013-08-22 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS |
CN107973788A (zh) * | 2018-01-09 | 2018-05-01 | 沈阳药科大学 | Bbi608衍生物及其制备与用途 |
CN109104862A (zh) * | 2016-03-01 | 2018-12-28 | 中央研究院 | 4,9-二氧代-4,9-二氢萘并[2,3-b]呋喃-3-羧酰胺衍生物及其用于治疗增生性疾病与感染性疾病的用途 |
CN110218198A (zh) * | 2019-05-22 | 2019-09-10 | 广州中医药大学(广州中医药研究院) | 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用 |
CN114591306A (zh) * | 2022-03-03 | 2022-06-07 | 陕西中医药大学 | 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用 |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113952459A (zh) | 2005-02-03 | 2022-01-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
CA2626326C (en) | 2005-11-04 | 2021-02-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
US9745278B2 (en) | 2007-09-10 | 2017-08-29 | Boston Biomedical, Inc. | Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
US20130331294A1 (en) | 2007-11-09 | 2013-12-12 | Fox Chase Cancer Center | Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
SG191676A1 (en) | 2008-06-17 | 2013-07-31 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
UA103492C2 (ru) | 2008-07-08 | 2013-10-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats) |
PT2326329T (pt) | 2008-08-04 | 2017-02-14 | Wyeth Llc | Combinações antineoplásicas de 4-anilino-3-cianoquinolinas e capecitabina |
AU2009322625A1 (en) | 2008-12-01 | 2011-07-21 | University Of Central Florida Research Foundation, Inc. | Drug composition cytotoxic for pancreatic cancer cells |
KR20190128004A (ko) | 2009-04-06 | 2019-11-13 | 와이어쓰 엘엘씨 | 네라티닙을 이용한 유방암의 치료법 |
CN101897979B (zh) * | 2009-05-27 | 2012-08-22 | 上海市计划生育科学研究所 | 治疗前列腺疾病的靶向药物 |
US20130129675A1 (en) * | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
EA022458B1 (ru) * | 2009-12-28 | 2016-01-29 | Дженерал Инкорпорейтед Ассошиэйшн Фарма Вэлли Проджект Саппортинг Организейшн | 1,3,4-оксадиазол-2-карбоксамидное соединение |
US20110275577A1 (en) * | 2010-01-08 | 2011-11-10 | Moleculin, Llc | Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs |
JP6017964B2 (ja) | 2010-03-01 | 2016-11-02 | ティーエーユー・セラピューティクス・エルエルシー | 癌診断および撮像 |
AU2015218436B9 (en) * | 2010-03-19 | 2017-03-09 | Boston Biomedical, Inc. | Novel Methods For Targeting Cancer Stem Cells |
US9730909B2 (en) | 2010-03-19 | 2017-08-15 | Boston Biomedical, Inc | Methods for targeting cancer stem cells |
CN107375260B (zh) | 2010-03-19 | 2023-10-24 | 北京强新生物科技有限公司 | 靶向癌症干细胞的新的化合物和组合物 |
RU2015142279A (ru) * | 2010-03-19 | 2018-12-28 | Бостон Байомедикал, Инк. | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
WO2011130677A1 (en) * | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibitors of cancer stem cells |
US20110301194A1 (en) * | 2010-06-02 | 2011-12-08 | Arqule, Inc. | Method for Determining Treatment Efficacy |
US8871802B2 (en) | 2010-08-24 | 2014-10-28 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Naphthoquinones for disease therapies |
WO2012036214A1 (ja) * | 2010-09-16 | 2012-03-22 | 国立大学法人大阪大学 | 自己免疫疾患、炎症性疾患、アレルギー性疾患、臓器移植に伴う症状の治療薬および予防薬 |
EP2643001A4 (en) * | 2010-11-22 | 2014-02-19 | Glaxosmithkline Ip Dev Ltd | METHOD OF TREATING CANCER |
WO2012071648A1 (en) * | 2010-11-30 | 2012-06-07 | London Health Sciences Centre Research Inc. | Egfr antagonist for the treatment of heart disease |
WO2012078982A2 (en) * | 2010-12-09 | 2012-06-14 | The Ohio State University | Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells |
KR20120130658A (ko) * | 2011-05-23 | 2012-12-03 | 주식회사 파멥신 | 펩타이드가 융합된 이중표적항체 및 그 용도 |
EP2717870B1 (en) * | 2011-06-06 | 2017-09-27 | Akebia Therapeutics Inc. | Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer |
CN103957923B (zh) * | 2011-09-12 | 2018-05-25 | 卡维昂公司 | 用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂 |
EP2776586B1 (en) * | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
KR102427777B1 (ko) | 2012-06-26 | 2022-08-01 | 델 마 파마슈티컬스 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
CN103705926A (zh) * | 2012-10-08 | 2014-04-09 | 贾力 | 预防原发性肿瘤在手术切除后再转移的药用组合物 |
DE102013003107A1 (de) | 2013-02-25 | 2014-09-11 | Thomas Rühl | Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung |
WO2014168986A1 (en) | 2013-04-08 | 2014-10-16 | Brown Dennis M | Therapeutic benefit of suboptimally administered chemical compounds |
MX2015014181A (es) * | 2013-04-09 | 2016-05-24 | Boston Biomedical Inc | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. |
CN105339390A (zh) * | 2013-04-29 | 2016-02-17 | Ogd2药物 | 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略 |
US10745489B2 (en) | 2013-04-29 | 2020-08-18 | Ogd2 Pharma | Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer |
MY175778A (en) | 2013-10-04 | 2020-07-08 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2016009655A (es) * | 2014-01-27 | 2016-11-09 | Boston Biomedical Inc | Metodos novedosos para el tratamiento del cancer. |
CN109867647A (zh) * | 2014-02-07 | 2019-06-11 | 北京强新生物科技有限公司 | 3-取代的羰基萘并[2,3-b]呋喃衍生物或其药学上可接受的盐 |
US11406707B2 (en) | 2014-02-10 | 2022-08-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | STAT3 phosphorylation during graft-versus-host disease |
SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US11230719B2 (en) * | 2014-03-26 | 2022-01-25 | Denovo Biopharma Llc | Retroviral vector having immune-stimulating activity |
WO2015164870A1 (en) | 2014-04-25 | 2015-10-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gamma-aa-peptide stat3/dna inhibitors and methods of use |
WO2015171985A1 (en) * | 2014-05-09 | 2015-11-12 | The Brigham And Women's Hospital, Inc. | Treatment of igg-immune complex-mediated organ damage |
AU2015272560B2 (en) * | 2014-06-09 | 2019-02-14 | Kyoto Pharmaceutical Industries, Ltd. | Novel anticancer agent |
EP3169326B1 (en) * | 2014-07-15 | 2021-03-31 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
US10906914B2 (en) | 2015-01-08 | 2021-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Furoquinolinediones as inhibitors of TDP2 |
JP6630364B2 (ja) | 2015-03-27 | 2020-01-15 | ボストン バイオメディカル, インコーポレイテッド | 水溶性プロドラッグ |
CN104693280A (zh) * | 2015-04-06 | 2015-06-10 | 苏州普罗达生物科技有限公司 | 信号传导及转录激活因子抑制多肽及其应用 |
CN104693279A (zh) * | 2015-04-06 | 2015-06-10 | 苏州普罗达生物科技有限公司 | 关于信号传导及转录激活因子抑制多肽及其应用 |
CN104725480A (zh) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | 一种信号传导及转录激活因子抑制多肽及其应用 |
EA201792287A1 (ru) | 2015-04-17 | 2018-03-30 | Бостон Биомедикал, Инк. | Способы лечения рака |
CN107708700A (zh) * | 2015-04-17 | 2018-02-16 | 波士顿生物医药有限公司 | 用于治疗癌症的方法 |
EA201792286A1 (ru) * | 2015-04-17 | 2018-03-30 | Бостон Биомедикал, Инк. | Способы лечения рака |
CA2983468A1 (en) * | 2015-04-27 | 2016-11-03 | Boston Biomedical, Inc. | Stat3 compounds and kinase inhibitors for the treatment of cancer |
DK3197456T3 (en) | 2015-05-14 | 2018-06-06 | NuCana plc | CANCER TREATMENTS |
JP6949726B2 (ja) * | 2015-05-15 | 2021-10-13 | ノバルティス アーゲー | Egfr変異癌を治療する方法 |
JP2018521979A (ja) * | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル, インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
WO2017013865A1 (ja) * | 2015-07-17 | 2017-01-26 | 大日本住友製薬株式会社 | 2-アセチル-4H,9H-ナフト[2,3-b]フラン-4,9-ジオンの製造方法 |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
WO2017023866A1 (en) * | 2015-07-31 | 2017-02-09 | Boston Biomedical, Inc. | Method of targeting stat3 and other non-druggable proteins |
JP6980649B2 (ja) | 2015-09-14 | 2021-12-15 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法 |
EA037248B1 (ru) | 2015-10-05 | 2021-02-26 | НУКАНА ПиЭлСи | Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином |
AU2017205478A1 (en) * | 2016-01-07 | 2018-06-28 | Swadesh K. Das | A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP) |
CA3011800A1 (en) * | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
JP6936214B2 (ja) * | 2016-03-25 | 2021-09-15 | 大日本住友製薬株式会社 | 2−アルキルカルボニルナフト[2,3−b]フラン−4,9−ジオンの関連物質の製造方法、及びその関連物質 |
JP2017171640A (ja) * | 2016-03-25 | 2017-09-28 | 学校法人兵庫医科大学 | 癌の治療システム |
CN105837541A (zh) * | 2016-04-23 | 2016-08-10 | 何淑琼 | 磷酸苯丙哌林的药物组合物及其在生物医药中的应用 |
CN105906595A (zh) * | 2016-04-23 | 2016-08-31 | 陈斌 | 丙酸倍氯米松的药物组合物及其在生物医药中的应用 |
GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA3029596A1 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
CN106380456B (zh) * | 2016-08-29 | 2019-03-26 | 中南大学 | 一种合成苯并呋喃萘醌衍生物的方法 |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
WO2018096401A1 (en) | 2016-11-22 | 2018-05-31 | Hitoshi Ban | New naphtho[2,3-b]furan derivatives |
WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
WO2018102506A1 (en) * | 2016-11-30 | 2018-06-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
CN108778275A (zh) * | 2017-01-22 | 2018-11-09 | 江苏恒瑞医药股份有限公司 | Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途 |
WO2018183908A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル, インコーポレイテッド | がんを処置するための方法 |
CA3066053A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
EP3654841B1 (en) * | 2017-07-20 | 2024-02-07 | Board Of Supervisors Of Louisiana State University | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients |
US20200207782A1 (en) | 2017-09-22 | 2020-07-02 | Sumitomo Dainippon Pharma Co., Ltd | Chemically activated water-soluble prodrug |
BR112020009596A2 (pt) * | 2017-11-16 | 2020-11-03 | Tyrnovo Ltd. | combinações de moduladores duplos de irs/stat3 e anticorpos anti pd-1/pd-l1 para tratar câncer |
EP3501511A1 (en) * | 2017-12-22 | 2019-06-26 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos III | Means for preventing and treating brain metastasis |
EP3733840A4 (en) * | 2017-12-28 | 2021-11-24 | Kaneka Corporation | INHIBITOR OF PLURIPOTENT STEM CELL AGGREGATION |
KR20200135401A (ko) * | 2018-03-20 | 2020-12-02 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 디히드로크로멘 유도체 |
HUE059318T2 (hu) * | 2018-04-19 | 2022-11-28 | Tvardi Therapeutics Inc | STAT3 inhibitorok |
WO2019232214A1 (en) | 2018-05-31 | 2019-12-05 | Boston Biomedical, Inc. | Methods of using napabucasin |
CN112703001A (zh) * | 2018-09-18 | 2021-04-23 | 株式会社益力多本社 | 使用喹啉羧酰胺衍生物的癌症联用疗法 |
CA3115869A1 (en) | 2018-10-12 | 2020-04-16 | 1Globe Biomedical Co., Ltd. | New combination solution for treating chemotherapy refractory cancer |
CN109331004A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物 |
CN109200044A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物 |
CN109223758A (zh) * | 2018-10-31 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴类stat3抑制剂联合用药物组合物 |
CN109966297A (zh) * | 2018-10-31 | 2019-07-05 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物 |
CN109288846A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物 |
CN109200052A (zh) * | 2018-10-31 | 2019-01-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物 |
CN109288845A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法 |
CN109846888A (zh) * | 2018-10-31 | 2019-06-07 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物 |
CN109172563A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物 |
CN109288847A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物 |
CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
US20220211708A1 (en) * | 2019-04-09 | 2022-07-07 | Generos Biopharma Ltd. | Pharmaceutical combination of pimozide and methotrexate and use thereof |
US11564913B2 (en) * | 2019-05-03 | 2023-01-31 | Children's Hospital Medical Center | Compositions and methods for treating cancer |
WO2020251015A1 (ja) * | 2019-06-14 | 2020-12-17 | 大日本住友製薬株式会社 | 2-アルキルカルボニル[2,3-b]フラン-4,9-ジオンの製造方法、及びその製造中間体 |
JP7287929B2 (ja) | 2019-09-25 | 2023-06-06 | 住友ファーマ株式会社 | ジヒドロクロメン誘導体を含有する医薬 |
KR20220131224A (ko) * | 2019-11-20 | 2022-09-27 | 예일 유니버시티 | 허혈-재관류 손상 및/또는 폐 손상을 치료하기 위한 화합물, 조성물 및 방법 |
KR20220124170A (ko) * | 2019-12-05 | 2022-09-13 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 간 섬유증 및 섬유증 관련 기타 질환에 대한 엑소좀 기반 치료요법 |
CN115135326A (zh) * | 2020-03-16 | 2022-09-30 | 正大天晴药业集团股份有限公司 | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 |
US20230192601A1 (en) * | 2020-05-11 | 2023-06-22 | Purdue Research Foundation | Scaled-up synthesis of lomustine under control flow conditions |
WO2022022524A1 (en) * | 2020-07-27 | 2022-02-03 | Huazhong University Of Science & Technology | Prevention and/or treatment of a disease associated with stat3 |
WO2022216930A1 (en) * | 2021-04-08 | 2022-10-13 | Virginia Commonwealth University | Novel mda-9 antagonist with anti-metastatic potential |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2472133A (en) * | 1947-03-20 | 1949-06-07 | Du Pont | Thiophanthraquinone derivatives |
SU1049490A1 (ru) | 1982-05-18 | 1983-10-23 | Ордена Трудового Красного Знамени Институт Химии Ан Мсср | (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции |
JPS616149A (ja) | 1984-06-20 | 1986-01-11 | Mitsubishi Electric Corp | 無機絶縁体の製法 |
JPS63196576A (ja) * | 1987-02-10 | 1988-08-15 | Tetsuo Ikegawa | フラルナフトキノン誘導体と制癌剤及びその製造方法 |
EP0309926A3 (de) | 1987-09-29 | 1990-12-05 | Siemens Aktiengesellschaft | Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik |
JPH01121284A (ja) | 1987-11-06 | 1989-05-12 | Eisai Co Ltd | トコフェロール n,n−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩 |
EP0402192A1 (fr) | 1989-05-31 | 1990-12-12 | BODET, Jean Augustin | Article en carton ou matière analogue et procédé de fabrication |
JPH04139177A (ja) | 1989-12-28 | 1992-05-13 | Dainippon Ink & Chem Inc | フラルベンゾキノン誘導体及びその製造方法並びに制癌剤 |
EP0466094B1 (en) * | 1990-07-10 | 1999-03-24 | Canon Kabushiki Kaisha | Electrophotographic photosensitive member |
JP2942015B2 (ja) * | 1990-07-10 | 1999-08-30 | キヤノン株式会社 | 電子写真感光体およびそれを用いた電子写真装置 |
TW252136B (zh) * | 1992-10-08 | 1995-07-21 | Ciba Geigy | |
JP3598168B2 (ja) | 1996-03-18 | 2004-12-08 | 独立行政法人 科学技術振興機構 | 抗ウイルス剤 |
JPH1121284A (ja) | 1997-06-30 | 1999-01-26 | Kotobuki:Kk | フラノナフトキノン誘導体及びこれを含有する医薬 |
JPH1165141A (ja) * | 1997-08-11 | 1999-03-05 | Canon Inc | 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置 |
US6174913B1 (en) * | 1998-06-05 | 2001-01-16 | The University Of North Carolina At Chapel Hill | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
EP1146869A2 (en) | 1999-01-27 | 2001-10-24 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
DE60042968D1 (de) | 1999-04-01 | 2009-10-29 | Hana Biosciences Inc | Zusammensetzungen und methoden zur behandlung lymphoma |
US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
KR100466730B1 (ko) | 1999-08-02 | 2005-01-24 | 에프. 호프만-라 로슈 아게 | 신규한 선택적 레티노이드 작용물질 |
JP2001097860A (ja) | 1999-09-29 | 2001-04-10 | Japan Science & Technology Corp | 抗薬剤耐性菌剤と抗クラミジア剤 |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
AU2002307217A1 (en) * | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
GB0117696D0 (en) | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
CN1310652C (zh) | 2001-11-29 | 2007-04-18 | 特拉科斯有限公司 | 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法 |
JP2005533748A (ja) * | 2002-03-08 | 2005-11-10 | シグナル ファーマシューティカルズ,インコーポレイテッド | 増殖性障害および癌を治療、予防、または管理するための併用療法 |
EP1344533B1 (en) * | 2002-03-15 | 2006-08-23 | Natimmune A/S | Pharmaceutical compositions comprising mannose binding lectin |
AU2002336473A1 (en) | 2002-09-10 | 2004-04-30 | Dabur Research Foundation | Anti-cancer activity of carvedilol and its isomers |
EP1551392A4 (en) | 2002-09-17 | 2006-09-20 | Arqule Inc | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF |
TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
IS6633A (is) | 2002-11-22 | 2004-05-23 | Omega Farma Ehf. | Samsetningar af fínasteríð töflum |
EP2481814A3 (en) | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
US7238372B2 (en) | 2003-08-13 | 2007-07-03 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
US20050049207A1 (en) * | 2003-09-03 | 2005-03-03 | Kaufmann Doug A. | Method of treating and preventing cancer |
WO2005033048A2 (en) * | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Wnt pathway antagonists |
DK1706133T3 (da) | 2003-12-02 | 2011-01-17 | Cleveland Clinic Foundation | Fremgangsmåder til beskyttelse mod stråling ved anvendelse af flagellin |
CN1894215B (zh) * | 2003-12-11 | 2012-03-21 | 得克萨斯州大学系统董事会 | 治疗细胞增殖疾病的化合物 |
DE10359828A1 (de) | 2003-12-12 | 2005-07-28 | Zoser B. Dr.Rer.Nat. Salama | CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe |
CA2563305A1 (en) | 2004-04-09 | 2005-11-24 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
JP2004224802A (ja) | 2004-04-21 | 2004-08-12 | Japan Science & Technology Agency | 抗菌剤 |
MX2007000265A (es) * | 2004-07-02 | 2007-07-20 | Icos Corp | Compuestos utiles para inhibir chk1. |
US20070249636A1 (en) * | 2004-08-18 | 2007-10-25 | Astrazeneca Ab | Selected Fused Heterocyclics and Uses Thereof |
US20060110462A1 (en) * | 2004-11-08 | 2006-05-25 | Pavlos Papadopoulos | Nanoparticulate compositions of tubulin inhibitor compounds |
EP1885352A2 (en) * | 2004-11-24 | 2008-02-13 | Novartis AG | Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
US7807662B2 (en) * | 2004-12-23 | 2010-10-05 | University Of South Florida | Platinum IV complex inhibitor |
EP1853242A4 (en) | 2005-02-25 | 2009-11-18 | Univ Michigan | SMALL STAT3 INHIBITORY MOLECULES AND USES THEREOF |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
JP2006290871A (ja) | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
WO2006126505A1 (ja) | 2005-05-26 | 2006-11-30 | The University Of Tokyo | Stat機能阻害剤およびその応用 |
US8133692B2 (en) * | 2005-07-20 | 2012-03-13 | University Of South Florida | Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments |
CA2625219A1 (en) | 2005-10-13 | 2007-04-19 | Orchid Research Laboratories Limited | Heterocyclic compounds as pstat3/il-6 inhibitors |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
AR057579A1 (es) * | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
JP2007145680A (ja) | 2005-11-30 | 2007-06-14 | Idemitsu Kosan Co Ltd | 水素発生材料および水素発生方法 |
US20090209494A1 (en) * | 2005-12-24 | 2009-08-20 | Christine Janet Martin | 21-deoxymacbecin analogues useful as antitumor agents |
WO2007087129A2 (en) * | 2006-01-12 | 2007-08-02 | Merck & Co., Inc. | Fluorinated arylamide derivatives |
EP2001438A2 (en) * | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
WO2007100640A2 (en) | 2006-02-21 | 2007-09-07 | The Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
AU2007218966A1 (en) * | 2006-02-24 | 2007-08-30 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles |
ES2533383T3 (es) | 2006-03-31 | 2015-04-09 | The Board Of Regents Of The University Of Texas System | Fármacos anticancerosos biodisponibles por vía oral relacionados con ácido cafeico |
US20070238770A1 (en) | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
US8828451B2 (en) * | 2006-10-04 | 2014-09-09 | University Of South Florida | Akt sensitization of cancer cells |
WO2008077062A2 (en) * | 2006-12-19 | 2008-06-26 | Board Of Regents, The University Of Texas System | Suppression of stat3 reactivation after src kinase inhibition to treat cancer |
JP4077863B1 (ja) | 2007-05-31 | 2008-04-23 | タヒボジャパン株式会社 | 抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法 |
US9745278B2 (en) | 2007-09-10 | 2017-08-29 | Boston Biomedical, Inc. | Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors |
US20100298402A1 (en) | 2007-11-06 | 2010-11-25 | Orchid Research Laboratories Limited | Stilbene derivatives as pstat3/il-6 inhibitors |
CN107375260B (zh) | 2010-03-19 | 2023-10-24 | 北京强新生物科技有限公司 | 靶向癌症干细胞的新的化合物和组合物 |
US9730909B2 (en) | 2010-03-19 | 2017-08-15 | Boston Biomedical, Inc | Methods for targeting cancer stem cells |
AU2015218436B9 (en) | 2010-03-19 | 2017-03-09 | Boston Biomedical, Inc. | Novel Methods For Targeting Cancer Stem Cells |
RU2015142279A (ru) | 2010-03-19 | 2018-12-28 | Бостон Байомедикал, Инк. | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
JP2014511384A (ja) | 2011-03-04 | 2014-05-15 | ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッド | 疾患治療のための4,9−ジヒドロキシ−ナフト[2,3−b]フランの新規エステル |
US8977803B2 (en) | 2011-11-21 | 2015-03-10 | Western Digital Technologies, Inc. | Disk drive data caching using a multi-tiered memory |
WO2013166618A1 (en) | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
MX2015014181A (es) | 2013-04-09 | 2016-05-24 | Boston Biomedical Inc | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. |
EA201792287A1 (ru) | 2015-04-17 | 2018-03-30 | Бостон Биомедикал, Инк. | Способы лечения рака |
EA201792286A1 (ru) | 2015-04-17 | 2018-03-30 | Бостон Биомедикал, Инк. | Способы лечения рака |
CN107708700A (zh) | 2015-04-17 | 2018-02-16 | 波士顿生物医药有限公司 | 用于治疗癌症的方法 |
CA2983468A1 (en) | 2015-04-27 | 2016-11-03 | Boston Biomedical, Inc. | Stat3 compounds and kinase inhibitors for the treatment of cancer |
JP2018521979A (ja) | 2015-06-03 | 2018-08-09 | ボストン バイオメディカル, インコーポレイテッド | 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物 |
CA3011800A1 (en) | 2016-01-20 | 2017-08-03 | Boston Biomedical, Inc. | Methods for treating cancer |
JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル, インコーポレイテッド | がんを処置するための方法 |
-
2008
- 2008-09-10 US US12/677,513 patent/US9745278B2/en active Active
- 2008-09-10 PT PT88304712T patent/PT2194987T/pt unknown
- 2008-09-10 PL PL08830471T patent/PL2194987T3/pl unknown
- 2008-09-10 DK DK16156335.8T patent/DK3050566T3/en active
- 2008-09-10 HU HUE08830471A patent/HUE027657T2/en unknown
- 2008-09-10 CN CN200880115249.XA patent/CN101854802B/zh active Active
- 2008-09-10 PL PL16156278T patent/PL3067054T3/pl unknown
- 2008-09-10 CN CN201310052882.1A patent/CN103288787B/zh active Active
- 2008-09-10 CA CA2736532A patent/CA2736532C/en active Active
- 2008-09-10 WO PCT/US2008/075903 patent/WO2009036099A1/en active Application Filing
- 2008-09-10 PT PT88306337T patent/PT2200431T/pt unknown
- 2008-09-10 SI SI200831606A patent/SI2190429T1/sl unknown
- 2008-09-10 SI SI200831626A patent/SI2194987T1/sl unknown
- 2008-09-10 CA CA2736564A patent/CA2736564A1/en not_active Abandoned
- 2008-09-10 JP JP2010524243A patent/JP5688840B2/ja not_active Expired - Fee Related
- 2008-09-10 PL PL08830633T patent/PL2200431T3/pl unknown
- 2008-09-10 EP EP08830633.7A patent/EP2200431B1/en active Active
- 2008-09-10 EP EP16156290.5A patent/EP3058941B1/en active Active
- 2008-09-10 HU HUE08830633A patent/HUE029111T2/en unknown
- 2008-09-10 ES ES08830471.2T patent/ES2583010T3/es active Active
- 2008-09-10 ES ES08830619.6T patent/ES2569215T3/es active Active
- 2008-09-10 WO PCT/US2008/075848 patent/WO2009036059A2/en active Application Filing
- 2008-09-10 CN CN201610134121.4A patent/CN105963289B/zh active Active
- 2008-09-10 JP JP2010524249A patent/JP5701603B2/ja not_active Expired - Fee Related
- 2008-09-10 DK DK08830619.6T patent/DK2190429T3/en active
- 2008-09-10 DK DK08830633.7T patent/DK2200431T3/en active
- 2008-09-10 CA CA2911990A patent/CA2911990C/en active Active
- 2008-09-10 CN CN201410583457.XA patent/CN104586832B/zh active Active
- 2008-09-10 CA CA2736563A patent/CA2736563C/en active Active
- 2008-09-10 DK DK08830471.2T patent/DK2194987T3/en active
- 2008-09-10 CN CN2008801152470A patent/CN101854937B/zh active Active
- 2008-09-10 EP EP16156278.0A patent/EP3067054B1/en active Active
- 2008-09-10 US US12/677,511 patent/US8877803B2/en not_active Expired - Fee Related
- 2008-09-10 EP EP16156335.8A patent/EP3050566B1/en active Active
- 2008-09-10 EP EP08830619.6A patent/EP2190429B1/en active Active
- 2008-09-10 JP JP2010524251A patent/JP5872160B2/ja not_active Expired - Fee Related
- 2008-09-10 WO PCT/US2008/075906 patent/WO2009036101A1/en active Application Filing
- 2008-09-10 US US12/677,516 patent/US9732055B2/en active Active
- 2008-09-10 SI SI200831655A patent/SI2200431T1/sl unknown
- 2008-09-10 ES ES08830633.7T patent/ES2584904T3/es active Active
- 2008-09-10 EP EP08830471.2A patent/EP2194987B1/en active Active
- 2008-09-10 PL PL08830619.6T patent/PL2190429T3/pl unknown
- 2008-09-10 HU HUE08830619A patent/HUE027443T2/en unknown
- 2008-09-10 CN CN200880115250.2A patent/CN101854930B/zh active Active
-
2011
- 2011-03-28 HK HK11103106.2A patent/HK1148943A1/xx unknown
- 2011-03-28 HK HK11103100.8A patent/HK1148942A1/zh unknown
- 2011-03-28 HK HK11103107.1A patent/HK1148906A1/zh unknown
-
2014
- 2014-09-02 JP JP2014177908A patent/JP5925849B2/ja not_active Expired - Fee Related
- 2014-09-02 JP JP2014177915A patent/JP5938072B2/ja not_active Expired - Fee Related
- 2014-09-29 US US14/499,299 patent/US9834532B2/en active Active
- 2014-11-17 JP JP2014232397A patent/JP2015034179A/ja not_active Withdrawn
- 2014-11-17 JP JP2014232396A patent/JP6106149B2/ja not_active Expired - Fee Related
-
2015
- 2015-11-26 JP JP2015230291A patent/JP6358659B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-13 JP JP2016004076A patent/JP6347795B2/ja not_active Expired - Fee Related
- 2016-02-01 JP JP2016016973A patent/JP6346628B2/ja not_active Expired - Fee Related
- 2016-04-21 HR HRP20160430TT patent/HRP20160430T1/hr unknown
- 2016-05-11 CY CY20161100393T patent/CY1117604T1/el unknown
- 2016-05-16 JP JP2016097607A patent/JP2016147906A/ja not_active Withdrawn
- 2016-06-07 HR HRP20160625TT patent/HRP20160625T1/hr unknown
- 2016-07-19 CY CY20161100701T patent/CY1118476T1/el unknown
- 2016-07-26 CY CY20161100733T patent/CY1117833T1/el unknown
- 2016-07-26 HR HRP20160949TT patent/HRP20160949T1/hr unknown
-
2017
- 2017-02-10 US US15/429,939 patent/US20170197932A1/en not_active Abandoned
- 2017-07-11 US US15/647,054 patent/US20180030021A1/en not_active Abandoned
- 2017-07-20 US US15/655,366 patent/US20180030022A1/en not_active Abandoned
- 2017-12-19 JP JP2017242778A patent/JP2018076349A/ja not_active Withdrawn
-
2018
- 2018-05-29 JP JP2018102234A patent/JP2018131464A/ja not_active Withdrawn
- 2018-10-16 US US16/161,413 patent/US10851075B2/en active Active
- 2018-12-31 US US16/236,948 patent/US20200039948A1/en not_active Abandoned
-
2019
- 2019-01-14 US US16/246,829 patent/US10377731B2/en not_active Expired - Fee Related
- 2019-02-21 JP JP2019029436A patent/JP2019073560A/ja active Pending
-
2020
- 2020-05-14 JP JP2020085065A patent/JP2020117547A/ja active Pending
- 2020-05-15 US US16/875,479 patent/US20210024482A1/en not_active Abandoned
- 2020-05-26 JP JP2020091326A patent/JP2020143135A/ja active Pending
- 2020-10-09 US US17/066,885 patent/US20210115006A1/en not_active Abandoned
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012119265A1 (en) * | 2011-03-04 | 2012-09-13 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | NOVEL ESTERS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR DISEASE THERAPIES |
CN103402993A (zh) * | 2011-03-04 | 2013-11-20 | 舟山海中洲新生药业有限公司 | 用于疾病治疗的4,9-二羟基-萘并[2,3-b] 呋喃新型酯 |
US9150530B2 (en) | 2011-03-04 | 2015-10-06 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies |
WO2013120229A1 (en) * | 2012-02-17 | 2013-08-22 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS |
CN104080449A (zh) * | 2012-02-17 | 2014-10-01 | 舟山海中洲新生药业有限公司 | 4,9-二羟基-萘并[2,3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法 |
CN109104862A (zh) * | 2016-03-01 | 2018-12-28 | 中央研究院 | 4,9-二氧代-4,9-二氢萘并[2,3-b]呋喃-3-羧酰胺衍生物及其用于治疗增生性疾病与感染性疾病的用途 |
US11434229B2 (en) | 2016-03-01 | 2022-09-06 | Academia Sinica | 4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases |
CN107973788A (zh) * | 2018-01-09 | 2018-05-01 | 沈阳药科大学 | Bbi608衍生物及其制备与用途 |
CN107973788B (zh) * | 2018-01-09 | 2021-07-09 | 沈阳药科大学 | Bbi608衍生物及其制备与用途 |
CN110218198A (zh) * | 2019-05-22 | 2019-09-10 | 广州中医药大学(广州中医药研究院) | 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用 |
WO2020232807A1 (zh) * | 2019-05-22 | 2020-11-26 | 广州中医药大学(广州中医药研究院) | 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用 |
CN110218198B (zh) * | 2019-05-22 | 2022-06-28 | 广州中医药大学(广州中医药研究院) | 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用 |
CN114591306A (zh) * | 2022-03-03 | 2022-06-07 | 陕西中医药大学 | 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用 |
CN114591306B (zh) * | 2022-03-03 | 2024-03-01 | 陕西中医药大学 | 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101854937B (zh) | 新的stat3途径抑制剂和癌症干细胞抑制剂 | |
TW199152B (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1148943 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1148943 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: 1GLOBE BIOLOGICAL (HONG KONG) CO., LTD. Free format text: FORMER OWNER: BOSTON BIOMEDICAL INC. Effective date: 20131029 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: HONG KONG, CHINA |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131029 Address after: Floor 31, Duke Mansion, landmark 15, Queen's road, Hongkong, China Patentee after: Strong biological (Hongkong) Co., Ltd. Address before: Massachusetts, USA Patentee before: Boston Biomedical Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING QIANGXIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: 1GLOBE BIOLOGICAL (HONG KONG) CO., LTD. Effective date: 20140124 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: HONG KONG, CHINA TO: 100083 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140124 Address after: 100083 Beijing City, Haidian District Xueyuan Road No. 30, large industrial building B block 8 room 01-15 Patentee after: Beijing Qiangxin Biotechnology Co., Ltd. Address before: Floor 31, Duke Mansion, landmark 15, Queen's road, Hongkong, China Patentee before: Strong biological (Hongkong) Co., Ltd. |